PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Kindeva Appoints Brok Weichbrodt as Chief Transformation Officer to Accelerate Growth Strategy and Commercial Excellence

Kindeva, a global drug delivery Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and accelerate growth as the company enters the next phase of its value creation plan.

With over 20 years of experience in the pharmaceutical and biotech sector, Brok has led large-scale transformation, built high-performing teams, and delivered complex operational programs. He previously played a key role in scaling Genezen from a viral vector start-up into a specialist CDMO, including executing 35 Drug product PPQ campaigns and commercializing 21 advanced programs. In this role, Brok will define and lead Kindeva’s transformation roadmap, aligning strategy with execution across operations, supply chain, and engineering across all business units. He will ensure Kindeva continues to scale effectively in a highly regulated environment, while delivering consistent, high-quality outcomes for customers and patients.

“Joining Kindeva at such an exciting stage of its growth journey is a fantastic opportunity. I’m looking forward to working with teams across the business to strengthen operational excellence, accelerate strategic execution, and help position Kindeva for its next phase of sustainable growth,” commented Brok on the news. 

He continued, “With experience leading organizations through more than 18 regulatory inspections, including by the FDA and EMA, I look forward to building on our strong foundations and working with our talented teams to deliver regulatory, quality and commercial excellence for our customers and patients.” 

David Stevens, CEO at Kindeva, said of the news: ” Brok brings a proven track record of leading enterprise transformation and translating strategy into measurable results. His experience across operations, quality, and complex program delivery will be critical as we strengthen our global network, improve reliability, and scale the business. We are delighted to welcome him as we enter the next phase of growth’

Find out more about Kindeva’s services here.

About Kindeva

Kindeva is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Manufacturing More Tomorrows™ for patients worldwide. We go beyond manufacturing to deliver strategic value through excellence in scalability and deep scientific expertise. Our comprehensive capabilities include Annex 1-aligned, state-of-the-art aseptic fill finish and next-generation sustainable inhalation propellant (NGP) technology. With proven expertise in pulmonary, nasal, dermal, and sterile injectable drug delivery, Kindeva partners with customers to meet today’s demands while delivering the possibilities of tomorrow. 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026